Disease

Name: ASPIRIN
Brand: ASPIRIN
Price: 4.66 USD
Availability: InStock
Rating: 4.1 (12 reviews)

What is steatotic liver disease?

Your liver is the largest organ inside your body. It helps you digest food, store energy, and remove harmful substances (toxins). Steatotic liver disease, formerly called fatty liver disease, happens when too much fat builds up in your liver. It's typical to have some fat in your liver cells, but too much can be a problem.

There are two main types of steatotic liver disease:

Metabolic dysfunction-associated steatotic liver disease (MASLD)
Alcohol-associated liver disease (ALD)

What is metabolic dysfunction-associated steatotic liver disease (MASLD)?

MASLD is a type of steatotic liver disease that is not caused by heavy alcohol use. It used to be called nonalcoholic fatty liver disease. There are two main forms:

Simple fatty liver, in which you have fat in your liver but little or no inflammation or liver damage. This form usually does not get bad enough to cause liver damage or complications.
Metabolic dysfunction-associated steatohepatitis, or MASH (previously called nonalcoholic steatohepatitis or NASH), is when MASLD gets worse. In addition to fat in your liver, MASH may cause inflammation and liver damage. This can lead to fibrosis, or scarring, of the liver. This scarring sometimes leads to cirrhosis or liver cancer.

What is alcohol-associated liver disease (ALD)?

ALD is caused by heavy alcohol use. It used to be called alcoholic fatty liver disease, or alcoholic steatohepatitis.

Your liver breaks down most of the alcohol you drink, so it can be removed from your body. But the process of breaking it down can create harmful substances. These substances can damage liver cells, cause inflammation, and weaken your body's natural defenses. The more alcohol that you drink, the more you damage your liver. ALD is the earliest stage of alcohol-related liver disease. The next stages are alcoholic hepatitis and cirrhosis.

Who is more likely to develop steatotic liver disease?

The cause of MASLD is unknown, but it is more common in people who:

Have type 2 diabetes and prediabetes
Have obesity
Are middle aged or older (although children can also get it)
Have high cholesterol or triglycerides
Have high blood pressure
Take certain medicines, such as corticosteroids and some cancer medicines
Have certain metabolic disorders, including metabolic syndrome
Have rapid weight loss
Have certain infections, such as hepatitis C
Have been exposed to certain harmful substances

MASLD is the most common chronic (long-term) liver disease due to increasing rates of obesity, type 2 diabetes, and high cholesterol.

ALD only happens in people who are heavy drinkers, especially those who have been drinking for a long period of time. The risk is higher for people who drink heavily and are women, have obesity, or have certain gene changes (known as variants or mutations).

What are the symptoms of steatotic liver disease?

Both MASLD and ALD usually have few or no symptoms. If you do have symptoms, you may feel tired or have discomfort in the upper right side of your abdomen (belly).

How is steatotic liver disease diagnosed?

Because there are often no symptoms, it's not easy to find steatotic liver disease. Your health care provider may suspect you have it if you have abnormal results on liver tests. To make a diagnosis, your provider may use:

Your medical history. This may include asking about your alcohol use and any medicines you take.
A physical exam. This may include checking your height and weight. Your provider may also check your body for signs of liver disease such as an enlarged liver or jaundice, a condition that causes your skin and whites of your eyes to turn yellow.
Blood tests. These may include liver function tests and blood count tests.
Imaging tests. These tests may be used to check for fat in the liver and for fibrosis.
A biopsy. In some cases, a biopsy may be done to confirm the diagnosis and check for liver damage.

What are the treatments for steatotic liver disease?

The first step in treating MASLD is usually weight loss. Losing weight can reduce fat in the liver, inflammation, and fibrosis. If your provider thinks that a certain medicine is the cause of your MASLD, they may tell you to stop or switch medicines. But don't stop taking any medicines unless your provider tells you to.

More studies are needed to see whether certain medicines are safe and effective to treat MASLD. Currently, no medicines are approved for treatment.

The most important part of treating ALD is to stop drinking alcohol. If you need help, you may benefit from counseling, a recovery program, or medicines that reduce cravings or make you feel sick if you drink alcohol.

Both ALD and one type of MASLD can lead to cirrhosis. Health problems caused by cirrhosis may be treated with medicines, surgery, and other medical procedures. If cirrhosis leads to liver failure, you may need a liver transplant.

What are some lifestyle changes that can help with steatotic liver disease?

If you have any type of steatotic liver disease, there are some lifestyle changes that can help:

Eat a healthy diet, limiting salt and sugar, plus eating lots of fruits, vegetables, and whole grains.
Talk with your provider about vaccinations. If you have chronic liver disease you are more likely to get infections. Your provider may recommend vaccinations for hepatitis A and B, the flu and pneumococcal disease.
Get regular exercise, which can help you lose weight and reduce fat in the liver.

Check with your provider before using dietary supplements, such as vitamins, or any complementary or alternative medicines or medical practices. Some supplements or herbal remedies can damage the liver.

Disease FDA Approved Drugs

ACCUNEB [Albuterol Sulfate^{2C₁₃H₂₁NO₃H₂O₄S}]

eq 0.021% base (inhalation solution)

eq 0.042% base (inhalation solution)

Mylan Speciality Lp^{Apr 30, 2001}

Indicated for the relief of bronchospasm in patients 2-12 years of age with asthma (reversible obstructive airway disease).

ALTOPREV [Lovastatin^{C₂₄H₃₆O₅}]

20mg (oral tablet, extended release)

40mg (oral tablet, extended release)

60mg (oral tablet, extended release)

Covis Pharma Bv^{Jun 26, 2002}

Method of decreasing the production of a-beta using a composition which decreases blood cholesterol in patients at risk of or exhibiting symptoms of alzheimer's disease.

ALVESCO [Ciclesonide^{C₃₂H₄₄O₇}]

0.08mg/inh (inhalation aerosol, metered)

0.16mg/inh (inhalation aerosol, metered)

Takeda Gmbh^{Jan 10, 2008}

Maintenance treatment of asthma as prophylactic therapy in adult and adolescent patients 12 years of age and older. patent claims method for treating a respiratory disease in a child.
Method of treating inflammatory conditions.

ANORO ELLIPTA [Umeclidinium Bromide^{C₂₉H₃₄NO₂Br} : Vilanterol Trifenatate^{C₂₄H₃₃Cl₂NO₅C₂₀H₁₆O₂}]

eq 0.0625mg base/inh : eq 0.025mg base/inh (inhalation powder)

Glaxosmithkline^{Dec 18, 2013}

Indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema..

ARCAPTA NEOHALER [Indacaterol Maleate^{C₂₄H₂₈N₂O₃C₄H₄O₄}]

eq 75mcg base (inhalation powder)

Sunovion Pharms Inc^{Jul 1, 2011}

The long term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema.

ASPIRIN [Aspirin^C₉H₈O₄]

OTC

325mg (oral capsule)

Plx Pharma^{Jan 14, 2013}

Temporary reduction of fever.
Temporary relief of minor aches and pains.
Treatment/prevention of cardiovascular disease.

AUSTEDO [Deutetrabenazine^{C₁₉H₂₇NO₃}]

12mg (oral tablet)

6mg (oral tablet)

9mg (oral tablet)

Teva Branded Pharm^{Apr 3, 2017}

Treatment of a neurodegenerative disease or a symptom thereof.

AZILECT [Rasagiline Mesylate^{C₁₂H₁₃NCH₄O₃S}]

eq 0.5mg base (oral tablet)

eq 1mg base (oral tablet)

Teva^{May 16, 2006}

Treatment of parkinson's disease.

BEVESPI AEROSPHERE [Formoterol Fumarate^{2C₁₉H₂₄N₂O₄C₄H₄O₄2H₂O} : Glycopyrrolate^{C₁₉H₂₈NO₃Br}]

0.0048mg/inh : 0.0090mg/inh (inhalation aerosol, metered)

Astrazeneca Pharms^{Apr 25, 2016}

Use in the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd).

BRILINTA [Ticagrelor^{C₂₃H₂₈F₂N₆O₄S}]

60mg (oral tablet)

90mg (oral tablet)

Astrazeneca Pharms^{Sep 3, 2015}

Method of inhibiting platelet aggregation.
Reduction of the rate of cardiovascular death, myocardial infarction, and stroke in patients with a history of myocardial infarction.
Reduction of the rate of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome or a history of myocardial infarction.
Reduction of the rate of thrombotic events in patients with acute coronary syndrome.
Treatment of an arterial thrombotic complication in a patient with coronary artery, cerebrovascular or peripheral vascular disease.
Treatment of arterial thrombotic complications selected from the group consisting of unstable angina, thrombotic or embolic stroke, transient ischaemic attacks, peripheral vascular disease and myocardial infarction.
Treatment of myocardial infarction and stroke in patients with acute coronary syndrome or a history of myocardial infarction.
Treatment of myocardial infarction in patients with acute coronary syndrome or a history of myocardial infarction.
Treatment of myocardial infarction.
Treatment of post-myocardial infarction.
Treatment of stable and unstable angina.
Treatment of stroke in patients with acute coronary syndrome or a history of myocardial infarction.
Treatment of stroke.
Treatment of thrombotic stroke.

BROVANA [Arformoterol Tartrate^{C₁₉H₂₄N₂O₄C₄H₆O₆}]

eq 0.015mg base/2ml (inhalation solution)

Sunovion^{Oct 6, 2006}

For the long term treatment, twice daily (morning and evening) maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and emphysema.

CARNITOR [Levocarnitine^{C₇H₁₅NO₃}]

1gm/10ml (oral solution)

200mg/ml (injection injectable)

330mg (oral tablet)

Leadiant Biosci Inc^{Apr 10, 1986}

CERDELGA [Eliglustat Tartrate^{2C₂₃H₃₆N₂O₄C₄H₆O₆}]

eq 84mg base (oral capsule)

Genzyme Corp^{Aug 19, 2014}

Treatment of gaucher disease type 1.

COMTAN [Entacapone^{C₁₄H₁₅N₃O₅}]

200mg (oral tablet)

Orion Pharma^{Oct 19, 1999}

Treatment of parkinson's disease.

CRESTOR [Rosuvastatin Calcium^{2C₂₂H₂₇FN₃O₆SCa}]

10mg (oral tablet)

20mg (oral tablet)

40mg (oral tablet)

5mg (oral tablet)

Ipr^{Aug 12, 2003}

Treatment of pediatric patients 8 to 17 years of age with heterozygous familial hypercholesterolemia (hefh).
Use of rosuvastatin calcium for the primary prevention of cardiovascular disease in individuals without clinically evident coronary heart disease but with increased risk factors.
Use of rosuvastatin calcium to reduce elevated total-c, ldl-c, apob, nonhdl-c or tg levels; to increase hdl-c in adult patients with primary hyperlipidemia or mixed dyslipidemia; and to slow the progression of atherosclerosis..

DEXILANT [Dexlansoprazole^{C₁₆H₁₄F₃N₃O₂S}]

30mg (oral capsule, delayed release)

60mg (oral capsule, delayed release)

Takeda Pharms Usa^{Jan 30, 2009}

For healing of all grades of erosive esophagitis (ee).
For the treatment of heartburn associated with symptomatic non-erosive gastroesophageal disease (gerd).
Healing of all grades of erosive esophagitis (ee) for up to 8 weeks.
Maintain healing of erosive esophagitis (ee) for up to 6 months.
To maintain healing of ee and relief of heartburn.
Treatment of heartburn associated with non-erosive gastroesophageal reflux disease (gerd) for 4 weeks.
Use of dexlansoprazole in patients taking clopidogrel without meaningful cyp2c19 interactions.

DEXILANT SOLUTAB [Dexlansoprazole^{C₁₆H₁₄F₃N₃O₂S}]

30mg (oral tablet, orally disintegrating, delayed release)

Takeda Pharms Usa^{Jan 26, 2016}

Maintain healing of erosive esophagitis (ee) for up to 6 months.
Treatment of heartburn associated with non-erosive gastroesophageal reflux disease (gerd) for 4 weeks.

ELELYSO [Taliglucerase Alfa]

200 units/vial (iv (infusion) powder)

Pfizer^{May 1, 2012}

A method of catalyzing the hydrolysis of glucocerebroside to glucose and ceramide..
A method of treating gaucher's disease.

FASLODEX [Fulvestrant^{C₃₂H₄₇F₅O₃S}]

50mg/ml (intramuscular injectable)

Astrazeneca^{Apr 25, 2002}

Treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.
Treatment of hr-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer in combination with palbococlib in women with disease progression after endocrine therapy.

FOSRENOL [Lanthanum Carbonate^{3CO₃2LaH₂O}]

eq 1gm base (oral powder)

eq 500mg base (oral tablet, chewable)

eq 750mg base (oral powder)

Shire Dev Llc^{Sep 24, 2014}
Shire Llc^{Nov 23, 2005}

To reduce serum phosphate in patients with end stage renal disease.

GILENYA [Fingolimod^{C₁₉H₃₃NO₂}]

0.5mg (oral capsule)

Novartis^{Sep 21, 2010}

Treatment of autoimmune disease.

GILOTRIF [Afatinib Dimaleate^{C₂₄H₂₅ClFN₅O₃2C₄H₄O₄}]

eq 20mg base (oral tablet)

eq 30mg base (oral tablet)

eq 40mg base (oral tablet)

Boehringer Ingelheim^{Jul 12, 2013}

Treatment of cancer.
Treatment of patients with advanced (metastatic) non-small cell lung cancer whose disease progressed during or after platinum-based chemotherapy.

GLEEVEC [Imatinib Mesylate^{C₂₉H₃₁N₇OCH₄O₃S}]

eq 100mg base (oral tablet)

eq 400mg base (oral tablet)

Novartis^{Apr 18, 2003}

A method for treating a tumor disease.
Gleevec is also indicated for the treatment of patients with kit (cd117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (gist).
Treatment of gastrointestinal stromal tumors (gist).

IBRANCE [Palbociclib^{C₂₄H₂₉N₇O₂}]

100mg (oral capsule)

125mg (oral capsule)

75mg (oral capsule)

Pfizer Inc^{Feb 3, 2015}

Treating hr-pos., her2-neg. advanced or metastatic breast cancer with palbociclib in combo with an aromatase inhibitor as initial endocrine based therapy in postmenopausal women or fulvestrant in women with disease progression after endocrine therapy.

INCRUSE ELLIPTA [Umeclidinium Bromide^{C₂₉H₃₄NO₂Br}]

eq 62.5mcg base/inh (inhalation powder)

Glaxo Grp England^{Apr 30, 2014}

Indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema..

KENGREAL [Cangrelor^{C₁₇H₂₅Cl₂F₃N₅O₁₂P₃S₂}]

50mg/vial (iv (infusion) powder)

Chiesi Usa Inc^{Jun 22, 2015}

Method of treating, reducing the incidence of, or preventing an ischemic event in a patient undergoing pci by administering intravenously 30 ug/kg bolus before pci and continuous infusion of 4 ug/kg/min for at least 2 hours or the duration of the pci.
P2y12 platelet inhibitor for use as adjunct to percutaneous coronary intervention to reduce risk of various diseases/conditions in patients not treated with a p2y12 platelet inhibitor and not given a glycoprotein iib/iiia inhibitor.

KYPROLIS [Carfilzomib^{C₄₀H₅₇N₅O₇}]

30mg/vial (intravenous powder)

60mg/vial (intravenous powder)

Onyx Therap^{Jun 3, 2016}

Kyprolis is indicated in combination with lenalidomide plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy.
Treatment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy.

MARQIBO KIT [Vincristine Sulfate^{C₄₆H₅₆N₄O₁₀H₂O₄S}]

5mg/5ml (1mg/ml) (intravenous injectable, liposomal)

Talon Therap^{Aug 9, 2012}

Treatment of adult patients with philadelphia chromosome-negative(ph-) acute lymphoblastic leukemia (all) in second or greater relapse or whose disease has progressed following two or more anti-leukemia therapies.

MIRAPEX ER [Pramipexole Dihydrochloride^{C₁₀H₁₇N₃S2ClHH₂O}]

0.375mg (oral tablet, extended release)

0.75mg (oral tablet, extended release)

1.5mg (oral tablet, extended release)

2.25mg (oral tablet, extended release)

3.75mg (oral tablet, extended release)

3mg (oral tablet, extended release)

4.5mg (oral tablet, extended release)

Boehringer Ingelheim^{Feb 19, 2010}

Treatment of parkinson's disease.

MULTAQ [Dronedarone Hydrochloride^{C₃₁H₄₄N₂O₅SClH}]

eq 400mg base (oral tablet)

Sanofi Aventis Us^{Jul 1, 2009}

Management of risk of dronedarone/beta-blocker interaction in patients in sinus rythm with a history of paroxysmal or persistent af.
Reduction in risk of hospitalization in patients with a history of paroxysmal or persistent af without severe heart failure and with one or more risk factors by administration twice a daily with morning and evening meals.
Reduction in risk of hospitalization in patients with coronary heart disease and a history of paroxysmal or persistent af and with one or more risk factors by administration twice a day with morning and evening meals.
Reduction in risk of hospitalization in patients with stable nyha class iii heart failure and a history of paroxysmal or persistent af and with one or more risk factors by administration twice a day with morning and evening meals.
Reduction of the risk of cardiovascular hospitalization.
Reduction of the risk of hospitalization for atrial fibrillation.
Treatment of patients with a history of paroxysmal or persistent af without severe heart failure and with one or more risk factors by administration twice a day with morning and evening meals.

NEUPRO [Rotigotine^{C₁₉H₂₅NOS}]

1mg/24hr (transdermal film, extended release)

2mg/24hr (transdermal film, extended release)

3mg/24hr (transdermal film, extended release)

4mg/24hr (transdermal film, extended release)

6mg/24hr (transdermal film, extended release)

8mg/24hr (transdermal film, extended release)

Ucb Inc^{Apr 2, 2012}

A method for the treatment of a patient suffering from a disease treatable with rotigotine, comprising applying the claimed transdermal delivery system (tds) to the skin of the patient.
Treatment of restless legs syndrome by application of claimed transdermal delivery system.
Treatment of signs and symptoms of parkinson's disease by application of claimed transdermal system.

NEXIUM [Esomeprazole Magnesium^{2C₁₇H₁₈N₃O₃SMg3H₂O}]

eq 10mg base/packet (oral for suspension, delayed release)

eq 2.5mg base/packet (oral for suspension, delayed release)

eq 20mg base (oral capsule, delayed rel pellets)

eq 20mg base/packet (oral for suspension, delayed release)

eq 40mg base (oral capsule, delayed rel pellets)

eq 40mg base/packet (oral for suspension, delayed release)

eq 5mg base/packet (oral for suspension, delayed release)

Astrazeneca Pharms^{Feb 27, 2008}

Pediatric use aged 1-11 years, gerd and erosive esophagitis.

NUPLAZID [Pimavanserin Tartrate^{2C₂₅H₃₄FN₃O₂C₄H₆O₆}]

eq 17mg base (oral tablet)

Acadia Pharms Inc^{Apr 29, 2016}

Treatment of a neurodegenerative disease or a symptom thereof.
Treatment of hallucinations and delusions associated with parkinson's disease psychosis.
Treatment of parkinson's disease psychosis.
Treatment of psychosis or a symptom thereof.
Treatment of psychosis.

PERFOROMIST [Formoterol Fumarate^{2C₁₉H₂₄N₂O₄C₄H₄O₄2H₂O}]

0.02mg/2ml (inhalation solution)

Mylan Speclt^{May 11, 2007}

Maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (copd).

PRADAXA [Dabigatran Etexilate Mesylate^{C₃₄H₄₁N₇O₅CH₄O₃S}]

eq 110mg base (oral capsule)

eq 150mg base (oral capsule)

eq 75mg base (oral capsule)

Boehringer Ingelheim^{Nov 20, 2015}

Method of reversing the anticoagulant effect of dabigatran using idarucizumab.
Prophylaxis or treatment of venous and arterial thrombotic disease.

PYLERA [Bismuth Subcitrate Potassium^{2C₆H₄O₇Bi5K3H₂O} : Metronidazole^{C₆H₉N₃O₃} : Tetracycline^{C₂₂H₂₄N₂O₈}]

140mg : 125mg : 125mg (oral capsule)

Forest Labs Llc^{Sep 28, 2006}

Pylera capsules, in combination with omeprazole are indicated for the treatment of patients with helicobacter pylori infection and duodenal ulcer disease to eradicate h. pylori.
Treatment of patients with h. pylori infection and duodenal ulcer disease.

RAYALDEE [Calcifediol^{C₂₇H₄₄O₂H₂O}]

0.03mg (oral capsule, extended release)

Opko Ireland Global^{Jun 17, 2016}

Administration of 25-hydroxyvitamin d3 by controlled release.
Treatment of secondary hyperparathyroidism in patients with stage 3 or 4 chronic kidney disease using controlled release, oral 25-hydroxyvitamin d.
Use of controlled release 25-hydroxyvitamin d in treating secondary hyperparathyroidism in patients having chronic kidney disease.
Use of extended release oral 25-hydroxyvitamin d3 in treating secondary hyperparathyroidism in adult patients having chronic kidney disease stage 3 or stage 4.
Use of sustained release 25-hydroxyvitamin d in treating patients having 25-hydroxyvitamin d insufficiency or deficiency.

RAYOS [Prednisone^{C₂₁H₂₆O₅}]

1mg (oral tablet, delayed release)

2mg (oral tablet, delayed release)

5mg (oral tablet, delayed release)

Horizon Pharma^{Jul 26, 2012}

Treatment of diseases or conditions by the use of a delayed release 1, 2, or 5 mg prednisone tablet.
Treatment of diseases or conditions by the use of a delayed-release 1,2, or 5mg prednisone tablet.
Treatment of pulmonary, gastrointestinal and/or rheumatological diseases or conditions by use of delayed release formulations of 1mg or 2mg prednisone.
Treatment of rheumatoid arthritis by delayed release formulation of 1mg or 2mg of prednisone.
Treatment of rheumatologic, allergic, pulmonary, gastrointestinal, dermatologic diseases or conditions by the use of a delayed release 5mg prednisone tablet.

REVLIMID [Lenalidomide^{C₁₃H₁₃N₃O₃}]

10mg (oral capsule)

15mg (oral capsule)

2.5mg (oral capsule)

20mg (oral capsule)

25mg (oral capsule)

Celgene^{Dec 27, 2005}

Treatment of male patient having a disease or condition responsive to a teratogenic drug.
Use of revlimid (lenalidomide) for the treatment of mantle cell lymphoma (mcl).
Use of revlimid (lenalidomide) for the treatment of multiple myeloma and transfusion-dependent anemia in myelodysplastic syndromes (mds).
Use of revlimid (lenalidomide) for the treatment of multiple myeloma.
Use of revlimid (lenalidomide) for the treatment of transfusion-dependent anemia in myelodysplastic syndromes (mds).
Use of revlimid (lenalidomide) to inhibit the secretion of pro-inflammatory cytokines, including tumor necrosis factor alpha.
Use of revlimid (lenalidomide) while preventing the exposure of a fetus or other contraindicated individual to revlimid (lenalidomide).

RYTARY [Carbidopa^{C₁₀H₁₄N₂O₄H₂O} : Levodopa^{C₉H₁₁NO₄}]

23.75mg : 95mg (oral capsule, extended release)

36.25mg : 145mg (oral capsule, extended release)

48.75mg : 195mg (oral capsule, extended release)

61.25mg : 245mg (oral capsule, extended release)

Impax Labs Inc^{Jan 7, 2015}

Method of providing a therapeutically effective and stable median blood plasma level of levodopa.
Treatment of parkinson's disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication.
Treatment of parkinson's disease.
Treatment of parkinsonism that may follow carbon monoxide intoxication or manganese intoxication.
Treatment of post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication.
Treatment of post-encephalitic parkinsonism.

SEEBRI [Glycopyrrolate^{C₁₉H₂₈NO₃Br}]

15.6mcg/inh (inhalation powder)

Sunovion Pharms Inc^{Oct 29, 2015}

Long - term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd).

SPIRIVA [Tiotropium Bromide]

eq 0.018mg base/inh (inhalation powder)

Boehringer Ingelheim^{Jan 30, 2004}

Administration of an inhalable powder comprising tiotropium via device.
For the long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (copd), including chronic bronchitis and emphysema.
Treatment of chronic obstructive pulmonary disease.

STALEVO 100 [Carbidopa^{C₁₀H₁₄N₂O₄H₂O} : Entacapone^{C₁₄H₁₅N₃O₅} : Levodopa^{C₉H₁₁NO₄}]

25mg : 200mg : 100mg (oral tablet)

Orion Pharma^{Jun 11, 2003}

Treatment of parkinson's disease.

STALEVO 125 [Carbidopa^{C₁₀H₁₄N₂O₄H₂O} : Entacapone^{C₁₄H₁₅N₃O₅} : Levodopa^{C₉H₁₁NO₄}]

31.25mg : 200mg : 125mg (oral tablet)

Orion Pharma^{Aug 29, 2008}

Treatment of parkinson's disease.

STALEVO 150 [Carbidopa^{C₁₀H₁₄N₂O₄H₂O} : Entacapone^{C₁₄H₁₅N₃O₅} : Levodopa^{C₉H₁₁NO₄}]

37.5mg : 200mg : 150mg (oral tablet)

Orion Pharma^{Jun 11, 2003}

Treatment of parkinson's disease.

STALEVO 200 [Carbidopa^{C₁₀H₁₄N₂O₄H₂O} : Entacapone^{C₁₄H₁₅N₃O₅} : Levodopa^{C₉H₁₁NO₄}]

50mg : 200mg : 200mg (oral tablet)

Orion Pharma^{Aug 2, 2007}

Treatment of parkinson's disease.

STALEVO 50 [Carbidopa^{C₁₀H₁₄N₂O₄H₂O} : Entacapone^{C₁₄H₁₅N₃O₅} : Levodopa^{C₉H₁₁NO₄}]

12.5mg : 200mg : 50mg (oral tablet)

Orion Pharma^{Jun 11, 2003}

Treatment of parkinson's disease.

STALEVO 75 [Carbidopa^{C₁₀H₁₄N₂O₄H₂O} : Entacapone^{C₁₄H₁₅N₃O₅} : Levodopa^{C₉H₁₁NO₄}]

18.75mg : 200mg : 75mg (oral tablet)

Orion Pharma^{Aug 29, 2008}

Treatment of parkinson's disease.

STRIVERDI RESPIMAT [Olodaterol Hydrochloride^{C₂₁H₂₆N₂O₅ClH}]

eq 0.0025mg base/inh (inhalation spray, metered)

Boehringer Ingelheim^{Jul 31, 2014}

Treatment of chronic obstructive pulmonary disease (copd), chronic bronchitis or emphysema.

SYMBICORT [Budesonide : Formoterol Fumarate Dihydrate]

0.08mg/inh : 0.0045mg/inh (inhalation aerosol, metered)

0.16mg/inh : 0.0045mg/inh (inhalation aerosol, metered)

Astrazeneca^{Jul 21, 2006}

Use for maintenance treatment of chronic obstructive pulmonary disease.
Use for the treatment of asthma in patients 6 years of age and older.

TARCEVA [Erlotinib Hydrochloride^{C₂₂H₂₃N₃O₄ClH}]

eq 100mg base (oral tablet)

eq 150mg base (oral tablet)

eq 25mg base (oral tablet)

Osi Pharms^{Nov 18, 2004}

First-line treatment of locally advanced unresectable or metastatic pancreatic cancer, in combination with gemcitabine.
First-line treatment of metastatic non smal-cell lung cancer (nsclc) with egfr exon 19 deletions or exon 21 (l858r) substitution mutations as detected by an fda-approved test.
Maintenance treatment in patients with locally advanced or metastatic nsclc who have not progressed on 1st-line treatment wth platinum-based chemotherapy.
Maintenance treatment of patients with locally advanced or metastatic nsclc whose disease has not progressed after four cycles platinum-based chemotherapy.
Treatment of locally advanced or metastatic non small-cell lung cancer (nsclc) after failure of at least one prior chemotherapy regimen.

TECFIDERA [Dimethyl Fumarate^C₆H₈O₄]

120mg (oral capsule, delayed release)

240mg (oral capsule, delayed release)

Biogen Idec Inc^{Mar 27, 2013}

Method of treating an autoimmune disease selected from autoimmune polyarthritis and multiple sclerosis but not treating psoriatic arthritis.
Method of treating multiple sclerosis.

THALOMID [Thalidomide^{C₁₃H₁₀N₂O₄}]

100mg (oral capsule)

150mg (oral capsule)

200mg (oral capsule)

Celgene^{Jan 17, 2003}

Acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (enl).
Approval for marketing only under a special restriction program approved by fda called 'system for thalidomide education and prescribing safety' (s.t.e.p.s.).
Maintenance therapy for prevention and supression of the cutaneous manifestations of enl recurrence.
Method for delivering a drug to a patient in need of the drug, while avoiding the occurence of an adverse side effect known or suspected of being caused by said drug.
Treatment of cutaneous manifestations of erythema nodosum leprosum (enl) in connection with a special program approved by fda called 'system for thalidomide education and prescribing safety' (s.t.e.p.s.).
Treatment of male patient having a disease or condition responsive to a teratogenic drug.
Use in combination with dexamethasone is indicated for the treatment of patients with newly diagnosed multiple myeloma.
Use of thalidomide in combination with dexamethasone for the treatment of patients with newly diagnosed multiple myeloma.
Use of thalidomide in treatment of cutaneous manifestations of erythema nodosum leprosum (enl).
Use of thalidomide while preventing the exposure of a fetus or other contraindicated individual to thalidomide.

TUDORZA PRESSAIR [Aclidinium Bromide^{C₂₆H₃₀NO₄S₂Br}]

0.4mg/inh (inhalation powder, metered)

Astrazeneca Pharms^{Jul 23, 2012}

Treatment of chronic obstructive pulmonary disease (copd) or chronic bronchitis.

TYZEKA [Telbivudine^{C₁₀H₁₄N₂O₅}]

600mg (oral tablet)

Novartis^{Oct 25, 2006}

Treatment of chronic hepatitis b in adult patients with evidence of viral replication and either evidence of persistant elevations in serum aminotransferases (alt or ast) or histologically active disease.
Treatment of chronic hepatitis b in adult patients.

UTIBRON [Glycopyrrolate^{C₁₉H₂₈NO₃Br} : Indacaterol Maleate^{C₂₄H₂₈N₂O₃C₄H₄O₄}]

15.6mcg/inh : 27.5mcg/inh (inhalation powder)

Sunovion Pharms Inc^{Oct 29, 2015}

Long - term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd).

VENTOLIN HFA [Albuterol Sulfate^{2C₁₃H₂₁NO₃H₂O₄S}]

eq 0.09mg base/inh (inhalation aerosol, metered)

Glaxosmithkline^{Apr 19, 2001}

The treatment or prevention of bronchospasm in adults and children 4 years of age and older with reversible obstructive airways disease and the prevention of exercised-induced bronchospasm in patients 4 years of age and older.

XADAGO [Safinamide Mesylate^{C₁₇H₁₉FN₂O₂CH₄O₃S}]

100mg (oral tablet)

50mg (oral tablet)

Us Worldmeds Llc^{Mar 21, 2017}

Adjunctive treatment to levodopa/carbidopa in patients with parkinson's disease experiencing 'off' episodes.

XIIDRA [Lifitegrast^{C₂₉H₂₄Cl₂N₂O₇S}]

5% (ophthalmic solution/drops)

Shire Dev Llc^{Jul 11, 2016}

Treatment of signs and symptoms of dry eye disease (ded).
Treatment of the signs symptoms of dry eye disease (ded).

YOSPRALA [Aspirin^C₉H₈O₄ : Omeprazole^{C₁₇H₁₉N₃O₃S}]

325mg : 40mg (oral tablet, delayed release)

81mg : 40mg (oral tablet, delayed release)

Aralez Pharms^{Sep 14, 2016}

Treatment or secondary prevention of cardiovascular disease, cardiovascular events, or cerebrovascular events and risk-reduction of aspirin-associated gastric ulcers.

ZETONNA [Ciclesonide^{C₃₂H₄₄O₇}]

0.037mg/inh (nasal aerosol, metered)

Takeda Gmbh^{Jan 20, 2012}

Method of treating inflammatory conditions.
Treatment of symptoms associated with seasonal and perennial allergic rhinitis in adults and adolescents 12 years of age and older. patent claims methods for treating a respiratory disease in a child.

WARNING: Consult a licensed physician in the appropriate field for medical treatment and drug prescription. Do not self medicate.

WARNING: All medicines, drugs, plants, chemicals or medicial precedures below are for reference only. Many of these treatments may be harmful and possibly fatal. Do not consume any plant, chemical, drug or otherwise without first consulting a licensed physician that practices medine in the appropriate field. The owner of this website will not be held liable for any injuries and deaths cause by following any home remedies. We have no control of what is posted.

Home Remedies for Disease

HEARTBURN [gastroesophageal reflux disease]
Eat a high-fiber diet that include beans.
Mechanism - Fiber helps move food out of the stomach faster reducing reflux.RudyardKipling | November 5th, 2017

Ledgend of Medicine

MODERN MEDICINES

HOME REMEDIES

RANDOM DRUGS

RANDOM AILMENTS

Disease

Disease FDA Approved Drugs

Home Remedies for Disease